Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study

Autor: Tøstesen M, Nørgaard M, Nørgaard JM, Medeiros BC, Marcher CW, Overgaard UM, Severinsen MT, Schoellkopf C, Østgård LSG

Publikováno v: Clinical Epidemiology, Vol Volume 11, Pp 769-780 (2019)

Michael Tøstesen,1 Mette Nørgaard,2 Jan Maxwell Nørgaard,3 Bruno C Medeiros,4 Claus Werenberg Marcher,5 Ulrik Malthe Overgaard,6 Marianne Tang Severinsen,7 Claudia Schoellkopf,8 Lene Sofie Granfeldt Østgård1–31Department of Clinical Medicine,

Externí odkaz: https://doaj.org/article/9da5334cfb794357aa1e22521f78abd1

The Danish National Acute Leukemia Registry

Autor: Østgård LSG, Nørgaard JM, Raaschou-Jensen KK, Pedersen RS, Rønnov-Jessen D, Pedersen PT, Dufva IH, Marcher CW, Nielsen OJ, Severinsen MT, Friis LS

Publikováno v: Clinical Epidemiology, Vol Volume 8, Pp 553-560 (2016)

Lene Sofie Granfeldt Østgård,1,2 Jan Maxwell Nørgaard,1 Klas Kræsten Raaschou-Jensen,3 Robert Schou Pedersen,4 Dorthe Rønnov-Jessen,5 Per Troellund Pedersen,6 Inge Høgh Dufva,7 Claus Werenberg Marcher,8 Ove Juul Nielsen,9 Marianne Tang Severins

Externí odkaz: https://doaj.org/article/b730a7e1481c47448800dabf70e3e2d7

Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy.

Autor: Kristensen DT; Department of Haematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Brøndum RF; Center for Clinical Data Science, Department of Clinical Medicine, Aalborg University and Research, Education, and Innovation, Aalborg University Hospital, Aalborg, Denmark., Ørskov AD; Department of Haematology, Zealand University Hospital, Roskilde, Denmark., Marcher CW; Department of Haematology, Odense University Hospital, Odense, Denmark., Schöllkopf C; Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Sørensen ALT; Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Severinsen MT; Department of Haematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Bøgsted M; Center for Clinical Data Science, Department of Clinical Medicine, Aalborg University and Research, Education, and Innovation, Aalborg University Hospital, Aalborg, Denmark., Roug AS; Department of Haematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.; Department of Haematology, Aarhus University Hospital, Aarhus, Denmark.

Publikováno v: European journal of haematology [Eur J Haematol] 2023 Oct; Vol. 111 (4), pp. 573-582. Date of Electronic Publication: 2023 Jul 25.

"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".

Autor: Rasmussen B; School of Medical Sciences, Örebro University, Örebro, Sweden., Göhring G; Department of Human Genetics, Hannover Medical School, Hannover, Germany., Bernard E; Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Nilsson L; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden., Tobiasson M; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden., Jädersten M; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden., Garelius H; Section for Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden., Dybedal I; Department of Hematology, Oslo University Hospital, Oslo, Norway., Grønbaek K; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Ejerblad E; Department of Medical Science, Section of Hematology, Uppsala University, Uppsala, Sweden., Lorenz F; Department of Medical Biosciences, Umeå University, Umeå, Sweden., Flogegård M; Department of Internal Medicine, Falun General Hospital, Falun, Sweden., Marcher CW; Department of Hematology, Odense University Hospital, Odense, Denmark., Öster Fernström A; Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine (HERM), Karolinska Institutet, Stockholm, Sweden., Cavelier L; Clinical Genomics Facility, Uppsala, Science for Life Laboratory IGP, Rudbeck Laboratory, Uppsala University and Clinical Genetics, Uppsala University Hospital, Uppsala, Sweden., Papaemmanuil E; Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ebeling F; Department of Medicine, Division of Hematology, Helsinki University Central Hospital, Helsinki, Finland., Kittang AO; Division for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway., Nørgaard JM; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Saft L; Department of Clinical Pathology, Division of Hematopathology, Karolinska University Hospital and Institute, Solna, Stockholm, Sweden., Möllgård L; Section for Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden., Hellström-Lindberg E; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. eva.hellstrom-lindberg@ki.se.

Publikováno v: Leukemia [Leukemia] 2022 May; Vol. 36 (5), pp. 1436-1439. Date of Electronic Publication: 2022 Mar 11.

Structural aberrations are associated with poor survival in patients with clonal cytopenia of undetermined significance.

Autor: Mikkelsen SU; Department of Hematology, Rigshospitalet, Copenhagen, Denmark; Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen., Safavi S; Department of Clinical Genetics, Rigshospitalet, Copenhagen., Dimopoulos K; Department of Clinical Biochemistry, Rigshospitalet, Copenhagen., O'Rourke CJ; Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen., Andersen MK; Department of Clinical Genetics, Rigshospitalet, Copenhagen., Holm MS; Department of Hematology, Aarhus University Hospital, Aarhus., Marcher CW; Department of Hematology, Odense University Hospital, Odense., Andersen JB; Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen., Hansen JW; Department of Hematology, Rigshospitalet, Copenhagen, Denmark; Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; DanStem, University of Copenhagen, Copenhagen., Grønbæk K; Department of Hematology, Rigshospitalet, Copenhagen, Denmark; Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; DanStem, University of Copenhagen, Copenhagen. Kirsten.Groenbaek@regionh.dk.

Publikováno v: Haematologica [Haematologica] 2021 Jun 01; Vol. 106 (6), pp. 1762-1766. Date of Electronic Publication: 2021 Jun 01.